Age is one of the most important prognostic factors in nonHodgkin's lymphoma (NHL). 1 It has been demonstrated that elderly patients have a lower complete remission (CR) Intensive chemotherapy with autologous bone marrow transplantation is now considered the treatment of rate and a shorter survival because of reduced dosage of active drugs and increased toxicity from chemotherapy. 2 In choice for young patients with sensitive relapse of nonHodgkin's lymphoma (NHL) but results of this prospite of an anthracycline-containing regimen, some patients failed to respond or experienced a recurrence. [3][4][5] In younger cedure in older patients remain unknown. We evaluated the feasibility of two cycles of salvage therapy followed patients with sensitive relapse, myeloablative chemotherapy followed by stem cell transplantation is currently the by an autologous peripheral blood stem cell (PBSC) transplantation in 13 patients aged more than 60 years method of choice to achieve long-term survival.
In order to evaluate the feasibility of this intensive pro-(median age: 62; range 61-72) suffering from relapsed (n = 10) or refractory (n = 3) aggressive NHL. All cedure in elderly patients, we investigated 13 patients aged more than 60 years with relapsed or refractory aggressive patients had previously received first-line treatment containing doxorubicin. An association of ifosfamide, NHL. Salvage chemotherapy consisted of a combination of ifosfamide, VP16 and cytosine-arabinoside with or without VP16, cytosine-arabinoside with or without high-dose methotrexate was used as salvage and priming therapy high-dose methotrexate (IVAM or IVA) followed by PBSC collection prior to transplantation. 7 Patients with sensitive prior to collection of PBSC. All patients received G-CSF following salvage therapy. PBSC collection could be disease and a sufficient number of PBSC underwent transplantation after a BEAM conditioning regimen. performed in 10 patients and yielded a median number of CFU-GM: 98.4 × 10 4 /kg (range 68-369). Nine patients underwent a transplantation using BEAM conditioning regimen. The median time to granulocyte and platelet Materials and methods recovery was 13 days (range respectively: 9-25 and 9-16). One patient died from sepsis after transplantation.
Patient characteristics The main adverse experience occurring after transplantation was a prolonged decline of performance status.
Patients over 60 years of age with relapsing or refractory aggressive NHL were considered eligible to receive therapy Seven patients achieved a complete remission and one failed to respond. Three patients are still alive in CR.
provided that they gave informed consent, had a performance status of 0, 1 or 2, and no severe organ impairment. We conclude that PBSC collection was possible in selected patients over 60 years of age with refractory or Relapse was defined as lymphoma recurrence at least 1 month after achieving a CR with front-line therapy. Refracrelapsed aggressive NHL and myeloablative therapy could be used with tolerable toxicity. Hematologic tory disease was defined as: (1) failure to obtain a CR at any time of the first treatment; or (2) progression on therapy recovery and organ toxicity appears to be similar to those observed in younger patients. Deterioration of or after achieving partial remission; or (3) early recurrence within the first month of CR. performance status after transplantation is the most important factor that could limit this procedure.
Thirteen consecutive patients were studied, and their characteristics are listed in and ifosfamide 1500 mg/m 2 for 3 days) followed by an 32 France).
LDH level Ͼnl 11
Myeloablative therapy a ACVBP = doxorubicin, cyclophosphamide, vindesine, bleomycine, prednisolone; CHOP = doxorubicin, cyclophosphamide, vincristine,
Myeloablative chemotherapy consisted of a BEAM regiprednisolone. men 9 (BCNU 300 mg/m 2 in 3 h infusion at day −7, cytarabine 100 mg/m 2 in 2-h infusions twice a day from days −6 to −3, etoposide 100 mg/m 2 in 2-h infusions twice a day 
Salvage chemotherapy
Among the 13 patients, three did not receive the second course of salvage chemotherapy because they progressed after the first course. Among those who received two tation was a decline in physical status. Before transplancourses, nine patients achieved a CR (seven out of eight tation, all patients had a performance status Ͻ2 according IVAM, and two out of five IVA) and one patient failed to to ECOG scale. At discharge, seven out of eight patients respond (one of five IVA). The median number of days had a performance status of 3. Two patients recovered with PMN Ͻ0.5 × 10 9 /l was 6 (range 4-13) after the first a grade 0 performance status respectively 2 and 5 course of salvage chemotherapy. Two severe infections months after transplantation. However, the remaining five (one grade 4 WHO grading, and one grade 3) occurred after patients relapsed before recovery of a normal performance IVAM and one (grade 3) after IVA.
status.
Tumor response and follow-up:
The patient who had active Leukaphereses disease at the time of transplantation died from lymphoma PBSC collection was performed in 10 patients. Harvest progression. Of the eight patients transplanted in CR, one could not be carried out in three patients, two patients died from toxicity at day 6 and the others remained in CR. because of disease progression and one because of a slow Five patients received post-transplant involved-field hemopoietic recovery after salvage therapy, despite the irradiation. Three patients are still alive in CR, the four administration of G-CSF. Three cytaphereses were necesother patients relapsed during the first 3 months after transsary to collect a sufficient CFU-GM number. 1 Two main factors may have (eight patients in CR, one patient in progression). The contributed to this worse prognosis, first, the reduced drug remaining patient could not receive the conditioning regidoses used in the elderly patients could lead to a decrease men because of rapid disease progression. After transplanin disease control with more frequent relapse or more resisttation, the median time to granulocyte (Ͼ0.5 × 10 9 /l) and ance; [6] [7] [8] [9] [10] second, an increase in treatment-related platelet recovery was 13 days (range 9-16 for granulocyte, deaths.
11-13
and 9-25 for platelets). Three patients were treated with GIn order to optimize the treatment in elderly patients, CSF after transplantation, neutrophil engraftment occurred some trials have used anthracycline-based chemotherapy in between day 12 and day 13. the same schedule as young patients. Recently, CHOP has proven to be the standard first-line treatment in the elderly with advanced intermediate-or high-grade NHL, resulting Toxicity: Acute and subacute toxicity is summarized in Table 3 . All patients developed severe marrow aplasia and in 49% CR and 42% 3-year survival. 4, 5 However, in spite of standard doses, some patients failed to respond and many neutropenic fever that required broad-spectrum antibiotics. One patient died of pseudomonas septicemia at day 6. No relapsed. The question of salvage therapy remains a real problem. It is now accepted that myeloablative chemolife-threatening graft failure, severe hemorrhagic episodes, marked mucositis requiring narcotic analgesia, drug-related therapy followed by autologous bone marrow transplantation is currently the best way to achieve long-term surcardiac, renal, pulmonary or hepatic toxicity were observed. The most important toxicity which occurred after transplanvival, in patients less than 60 years who have sensitive not influence the risk of relapse. Protocols used in younger
